Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 7/20 | 0.42 |
| ▸ | GNAI3 | P08754 | 6/20 | 0.42 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.33 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | SOD3 | P08294 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4308599 | 0.98 | GNAO1 (0.44) | GNAO1GNAI3GNAI1SIGMAR1OPRM1 | |
| SCHEMBL20363958 | 0.98 | GNAO1 (0.44) | GNAO1GNAI3GNAI1SIGMAR1OPRM1 | |
| SCHEMBL13636463 | 0.98 | GNAO1 (0.44) | GNAO1GNAI3GNAI1SIGMAR1OPRM1 | |
| SCHEMBL20363956 | 0.98 | GNAO1 (0.44) | GNAO1GNAI3GNAI1SIGMAR1OPRM1 | |
| SCHEMBL27736675 | 0.98 | GNAO1 (0.44) | GNAO1GNAI3GNAI1SIGMAR1OPRM1 | |
| Hydrochloric Acid SCHEMBL4377618 | 0.96 | GNAO1 (0.47) | GNAO1GNAI3GNAI1SIGMAR1OPRM1 | |
| SCHEMBL13380382 | 0.94 | SIGMAR1 (0.44) | GNAO1GNAI3GNAI1SIGMAR1KDM2B | |
| SCHEMBL24026518 | 0.91 | SIGMAR1 (0.40) | GNAO1GNAI3GNAI1SIGMAR1OPRM1 | |
| SCHEMBL27939602 | 0.89 | GNAI3 (0.36) | GNAO1GNAI3GNAI1SIGMAR1OPRM1 | |
| Iodide SCHEMBL28872656 | 0.87 | GNAI3 (0.35) | GNAO1GNAI3GNAI1SIGMAR1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6916797-B2 | α-arylethylpiperazine derivatives as neurokinin antagonists | UCB, S.A. (BE) | 2005-07-12 | — | — | US | claimed |
| EP-1242399-A1 | $g(a)-ARYLETHYLPIPERAZINE DERIVATIVES AS NEUROKININ ANTAGONISTS | UCB S.A. (BE) | 2002-09-25 | — | — | EP | claimed |
| WO-2001046167-A1 | α-ARYLETHYLPIPERAZINE DERIVATIVES AS NEUROKININ ANTAGONISTS | UCB, S.A. (BE) | 2001-06-28 | — | — | WO | claimed |
| US-20030220323-A1 | Alpha-arylethylpiperazine derivatives as neurokinin antagonists | UCB, S.A. (BE) | 2003-11-27 | — | — | US | disclosed |
| EP-1242399-A1 | $g(a)-ARYLETHYLPIPERAZINE DERIVATIVES AS NEUROKININ ANTAGONISTS | UCB S.A. (BE) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001046167-A1 | α-ARYLETHYLPIPERAZINE DERIVATIVES AS NEUROKININ ANTAGONISTS | UCB, S.A. (BE) | 2001-06-28 | — | — | WO | disclosed |
| EP-1110958-A1 | Alpha-arylethylpiperazine derivatives as neurokinin antagonists | UCB, S.A. (BE) | 2001-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220323-A1 | Alpha-arylethylpiperazine derivatives as neurokinin antagonists | TACR1, TACR2, NPSR1 | GNAO1 1189/4885GNAI3 1563/4885GNAI1 1314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.